Two patients clinically diagnosed with Alzheimer’s disease before our review—one amnestic (case 8) and one non-amnestic (case 3)—had biomarker changes compatible with the diagnosis, meeting the amyloid/tau/neurodegeneration, or AT(N), criteria for disorders within the Alzheimer’s continuum (Fig. 1 and Table 2)32. The gene discussed is MAPT; the disease is Alzheimer disease.